setback

In: Finance

Michael Vi/iStock Editorial via Getty Images Biotechs developing a class of novel cancer drugs called anti-TIGIT therapies turned lower in the premarket Friday after a similar drug developed by Roche (OTCQX:RHHBY) failed in a Phase 2/3 clinical trial. Roche (OTCQX:RHHBY) shares fell in European trading on Thursday after the SwissContinue Reading

In: Finance

Anne Czichos Shares of Merck KGaA (OTCPK:MKGAF) (OTCPK:MKKGY) fell in European trading on Tuesday after the German drugmaker said it would discontinue a late-stage trial for its head and neck cancer therapy xevinapant as its early results indicated a potential failure. The decision comes after the study’s data monitoring committeeContinue Reading